Feasibility randomized controlled trial by Seliger et al. | Journal of the American Society of Nephrology | Published online ahead of print on 24 October 2026.
In a 12-month randomized trial of 50 adults at high risk of rapid ADPKD progression, height-adjusted total kidney volume increased by 10.5% per year with empagliflozin versus 5.1% with placebo. Participants generally tolerated the drug. After an initial decline in estimated glomerular filtration rate (eGFR), the difference in eGFR slope over months 1–12 was statistically inconclusive.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors slow kidney function decline in several forms of chronic kidney disease, but the major trials excluded people with ADPKD. Because progressive cyst expansion enlarges the kidneys and can precede measurable loss of function, the investigators assessed both kidney volume and eGFR.
Two US centers enrolled adults aged 18–55 years without diabetes who were at high risk of ADPKD progression and were not taking tolvaptan. Mean baseline eGFR was 70 mL/min/1.73 m². Participants were randomized 1:1 to empagliflozin or placebo. Empagliflozin started at 10 mg once daily and increased to 25 mg once daily after one month if tolerated. Safety and tolerability were the primary outcomes. Kidney volume and eGFR were secondary outcomes.
| Outcome | Empagliflozin | Placebo | P value |
|---|---|---|---|
| Annual increase in height-adjusted total kidney volume | 10.5% (95% CI, 8.2%–12.7%) | 5.1% (95% CI, 3.0%–7.3%) | 0.001 |
| eGFR change at one month, mL/min/1.73 m² | −6.2 | +0.1 | 0.01 |
| Annualized eGFR slope from months 1–12, mL/min/1.73 m² per year | −0.77 | −2.87 | 0.40 |
| Participants who tolerated the full assigned dose | 96% | 96% | — |
Overall adverse-event frequency was similar. Urinary tract infections occurred in two empagliflozin recipients and no placebo recipients. One participant in the placebo group developed acute kidney injury. pubmed.ncbi.nlm.nih.gov
The 5.4-percentage-point difference in annual kidney-volume growth raises concern about accelerated kidney enlargement. Kidney volume was a secondary endpoint, and 12 months of follow-up in a 50-person feasibility trial leaves open whether the imaging difference translates into faster long-term loss of kidney function. The eGFR results also leave any longer-term functional benefit uncertain. pubmed.ncbi.nlm.nih.gov
These findings provide no basis for routine empagliflozin use to slow ADPKD progression and are consistent with KDIGO guidance against using SGLT2 inhibitors for that purpose. Larger, longer randomized trials are needed to determine whether the kidney-volume difference persists and whether it predicts a clinically meaningful change in kidney function. pubmed.ncbi.nlm.nih.gov
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition in which multiple fluid-filled cysts develop in both kidneys. As the cysts grow, the kidneys can enlarge and gradually lose their ability to filter blood. Progression varies widely. Most cases involve a disease-causing variant in PKD1 or PKD2. When one parent carries such a variant, each child has a 50% chance of inheriting it. NIDDK
ADPKD can be silent for years. Common signs include high blood pressure, flank or back pain, and blood in the urine. Kidney stones, urinary infections, and liver cysts may also occur. Ultrasound is usually the first imaging test in people with a family history. MRI or genetic testing can help when the diagnosis is uncertain. NIDDK
Why kidney size matters in this trial. The kidneys can enlarge before estimated glomerular filtration rate (eGFR) falls substantially. This is why the empagliflozin trial measured both height-adjusted total kidney volume, which tracks enlargement, and eGFR, which estimates filtration. The faster kidney enlargement observed in the trial raises concern, while its effect on long-term kidney function remains uncertain.